Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bibby

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Anti-Cancer Drug Design|October 1, 1989
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activityR S McElhinney, J E McCormick, M C Bibby, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 2, 2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatmentAnna C Bibby, Selina Tsim, Nikolaos Kanellakis, et al.
Anti-Cancer Drug Design|March 1, 1989
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functionsR S McElhinney, J E McCormick, M C Bibby, et al.
Teratogenesis, Carcinogenesis, and Mutagenesis|December 24, 2003
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of actionM Suggitt, J Fearnley, D J Swaine, et al.
Anticancer Research|May 23, 2002
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumoursS E Holwell, P A Cooper, K Grosios, et al.
Anti-Cancer Drug Design|June 1, 1989
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in miceR S McElhinney, J E McCormick, M C Bibby, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 1999
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humansC R Calabrese, P M Loadman, L S Lim, et al.
Molecular Cancer Therapeutics|November 16, 2004
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipidsSimon S Jensen, Thomas L Andresen, Jesper Davidsen, et al.
Anticancer Research|January 30, 2003
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphateS E Holwell, P A Cooper, M J Thompson, et al.
BMC Palliative Care|December 10, 2017
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre studyAnna C Bibby, Duneesha De Fonseka, Anna J Morley, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Anti-Cancer Drug Design|October 1, 1989
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activityR S McElhinney, J E McCormick, M C Bibby, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 2, 2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatmentAnna C Bibby, Selina Tsim, Nikolaos Kanellakis, et al.
Anti-Cancer Drug Design|March 1, 1989
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functionsR S McElhinney, J E McCormick, M C Bibby, et al.
Teratogenesis, Carcinogenesis, and Mutagenesis|December 24, 2003
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of actionM Suggitt, J Fearnley, D J Swaine, et al.
Anticancer Research|May 23, 2002
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumoursS E Holwell, P A Cooper, K Grosios, et al.
Anti-Cancer Drug Design|June 1, 1989
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in miceR S McElhinney, J E McCormick, M C Bibby, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 1999
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humansC R Calabrese, P M Loadman, L S Lim, et al.
Molecular Cancer Therapeutics|November 16, 2004
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipidsSimon S Jensen, Thomas L Andresen, Jesper Davidsen, et al.
Anticancer Research|January 30, 2003
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphateS E Holwell, P A Cooper, M J Thompson, et al.
BMC Palliative Care|December 10, 2017
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre studyAnna C Bibby, Duneesha De Fonseka, Anna J Morley, et al.
Pageof 21